ALBO - Albireo Pharma, Inc.
| Previous Close | 24.69 |
| Open | 24.68 |
| Bid | 20.16 x 900 |
| Ask | 25.94 x 800 |
| Day's Range | 24.61 - 25.08 |
| 52 Week Range | 16.13 - 38.69 |
| Volume | 74,182 |
| Avg. Volume | 110,045 |
| Market Cap | 368.064M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.80 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.17 |
- GlobeNewswire
Albireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. In addition, the underwriters have exercised in full an option to purchase an additional 285,750 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by Albireo, with gross proceeds to Albireo of approximately $46.0 million and net proceeds of approximately $42.9 million, after deducting underwriting discounts and commissions and estimated offering expenses.
- GlobeNewswire
Albireo Prices $40 Million Public Offering of Common Stock
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. Albireo’s gross proceeds from this offering are expected to be approximately $40 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 285,750 shares of common stock on the same terms and conditions.
- GlobeNewswire
Albireo Announces Proposed Public Offering of Common Stock
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the offering, Albireo intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering. All of the shares in the offering will be sold by Albireo.
- GlobeNewswire
Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once-daily capsule in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome. The U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application to initiate a global pivotal trial in biliary atresia.
- GlobeNewswire
Albireo Joins with Alagille Syndrome Community in Celebrating First International Awareness Day
Alagille syndrome community advocates for education and resources with first-ever disease awareness day. BOSTON, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, commemorates the first International Alagille Awareness Day on January 24, 2020, acknowledging pediatric hepatologist and researcher Dr. Daniel Alagille, who first characterized the syndrome. Alagille syndrome (ALGS) is a rare genetic disorder associated with liver, heart, eye and skeletal abnormalities without an approved pharmacological treatment.
- Insider Monkey
Do Hedge Funds Love Albireo Pharma, Inc. (ALBO)?
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]
- Barrons.com
Biotech Stocks Are In a Position to Break Out in 2020, Analysts Say
Biotech surged in the third quarter, approvals from the Food & Drug Administration are coming through above the average annual rate, the valuation of large-cap biotechs are attractive, and there have been significant mergers and acquisitions in past years.
- Simply Wall St.
Is Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Salary Justified?
Ron Cooper became the CEO of Albireo Pharma, Inc. (NASDAQ:ALBO) in 2015. This report will, first, examine the CEO...
- GlobeNewswire
Albireo to Present at the Jefferies 2019 London Healthcare Conference
BOSTON, Nov. 14, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- Insider Monkey
Were Hedge Funds Right About Souring On Albireo Pharma, Inc. (ALBO)?
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
- GlobeNewswire
Albireo Reports Third Quarter 2019 Financial Results and Provides Business Update
— Phase 3 PFIC trial randomization more than three-quarters complete. —— Topline results expected mid-2020. —— Pivotal trial in biliary atresia expected to be initiated in 2020..
- GlobeNewswire
Albireo Appoints Michelle Graham as Chief Human Resources Officer
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Michelle Graham has been appointed Chief Human Resources Officer, effective today. “We are delighted attract Michelle to Albireo during this pivotal period. “We are creating something special at Albireo, and our employees’ incredible work has accelerated our progress.
- Simply Wall St.
Will Albireo Pharma (NASDAQ:ALBO) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Albireo to Report Third Quarter 2019 Financial Results on November 6, 2019
BOSTON, Oct. 30, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- GlobeNewswire
Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today its support for PFIC Awareness Day, and reaffirmed its commitment to patients and families living with progressive familial intrahepatic cholestasis (PFIC). PFIC is an ultra-rare, life-threatening, pediatric liver disease characterized by pruritus (intense itching), jaundice (elevated serum bilirubin levels that may manifest as yellowing of the skin), and poor weight gain and growth. People with PFIC are often diagnosed in infancy or early childhood and can progress to cirrhosis and liver failure by age 10 without surgical intervention.
- GlobeNewswire
Albireo Announces Presentations at NASPGHAN 2019 Annual Meeting
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced upcoming presentations at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2019 Annual Meeting, being held October 16-19, 2019, in Chicago. The presentations will include pharmacological data regarding the Company’s lead product candidate, odevixibat, as well as background about the Company’s proprietary patient- and observer-reported outcomes assessment tools for pruritus. “When considering existing and emerging pediatric therapies, there is a strong desire among physicians, parents and patients for exposure levels to be concentrated in targeted areas of the body while minimizing broader systemic exposure,” said Ron Cooper, President and Chief Executive Officer of Albireo.
- Simply Wall St.
Is Albireo Pharma, Inc. (NASDAQ:ALBO) A Volatile Stock?
If you're interested in Albireo Pharma, Inc. (NASDAQ:ALBO), then you might want to consider its beta (a measure of...
- GlobeNewswire
Albireo to Participate in Upcoming Investor Conferences
BOSTON, Sept. 03, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
Motley FoolAlbireo Pharma, Inc. (ALBO) Q2 2019 Earnings Call Transcript
ALBO earnings call for the period ending June 30, 2019.
- GlobeNewswire
Albireo Reports Second Quarter 2019 Financial Results
— Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 —— Initiated elobixibat Phase 2 trial in NAFLD/NASH —— Management to host conference call and webcast today at 10.
- GlobeNewswire
Albireo to Present at Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 06, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- GlobeNewswire
Albireo to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast
BOSTON, Aug. 01, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- Zacks
Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for
Albireo Pharma (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Albireo Provides Mid-Year Clinical Development Update
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided an update on the progress of the development of odevixibat for pediatric cholestatic liver diseases and elobixibat for NASH. The odevixibat PEDFIC program in progressive familial intrahepatic cholestasis (PFIC) consists of two clinical trials.
